Koelle David M
University of Washington, Harborview Medical Center, Seattle 98104, USA.
Curr Opin Investig Drugs. 2006 Feb;7(2):136-41.
Infections with herpes simplex virus (HSV) type 1 (HSV-1) and type 2 (HSV-2) can have serious medical consequences. Although antiviral medications can suppress symptomatic disease, asymptomatic shedding and transmission, they neither cure nor alter the natural history of HSV infections. Manipulation of the immune response is one potential method to decrease disease burden. Current research on prophylactic and therapeutic vaccination approaches is discussed in this review, with a focus on compounds that have entered clinical trials or that display novel compositions or proposed mechanisms of action. One such vaccine is an alum and monophosphoryl lipid A-adjuvanted subunit glycoprotein D2 vaccine that has demonstrated activity in the prevention of HSV-2 infection and disease in HSV-uninfected women in a phase III clinical trial. Further confirmatory clinical trials of this vaccine are currently underway. Other vaccine formats also in development include attenuated live or replication-incompetent HSV-2 strains and technologies that target virus-specific CD8 T-cell responses.
1型单纯疱疹病毒（HSV-1）和2型单纯疱疹病毒（HSV-2）感染可产生严重的医学后果。尽管抗病毒药物可抑制症状性疾病、无症状排毒和传播，但它们既不能治愈HSV感染，也不能改变其自然病程。调节免疫反应是减轻疾病负担的一种潜在方法。本综述讨论了目前关于预防性和治疗性疫苗接种方法的研究，重点关注已进入临床试验或具有新型成分或作用机制的化合物。一种这样的疫苗是明矾和单磷酰脂质A佐剂亚单位糖蛋白D2疫苗，在一项III期临床试验中，该疫苗已证明对预防HSV未感染女性的HSV-2感染和疾病具有活性。目前正在对该疫苗进行进一步的验证性临床试验。其他正在研发的疫苗形式包括减毒活或无复制能力的HSV-2毒株以及针对病毒特异性CD8 T细胞反应的技术。
